Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical …
With the widespread use of atypical or second-generation antipsychotics, switching
treatment has become current practice and more complicated, as the pharmacological …
treatment has become current practice and more complicated, as the pharmacological …
Therapeutic drug monitoring of long-acting injectable antipsychotic drugs
G Schoretsanitis, P Baumann, A Conca… - Therapeutic drug …, 2021 - journals.lww.com
Background: The use of therapeutic drug monitoring (TDM) to guide treatment with long-
acting injectable (LAI) antipsychotics, which are increasingly prescribed, remains a matter of …
acting injectable (LAI) antipsychotics, which are increasingly prescribed, remains a matter of …
Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial
J Berwaerts, Y Liu, S Gopal, I Nuamah, H Xu… - JAMA …, 2015 - jamanetwork.com
Importance Treatment nonadherence and relapse are common problems in patients with
schizophrenia. The long-acting 3-month formulation of paliperidone palmitate, owing to its …
schizophrenia. The long-acting 3-month formulation of paliperidone palmitate, owing to its …
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: a phase‐1, single‐dose, randomized, open …
P Ravenstijn, B Remmerie, A Savitz… - the journal of clinical …, 2016 - Wiley Online Library
This multicenter, randomized, open‐label, parallel‐group, phase‐1 study assessed the
pharmacokinetics (PK), safety, and tolerability of the investigational intramuscular …
pharmacokinetics (PK), safety, and tolerability of the investigational intramuscular …
Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC–MS for investigating the …
M Zhao, J Tao, D Qian, P Liu, E Shang, S Jiang… - … of Chromatography B, 2016 - Elsevier
A sensitive and rapid method for determination of loganin, morroniside, catalpol and
acteoside in rat plasma after oral administration of Rehmannia glutinosa Libosch and …
acteoside in rat plasma after oral administration of Rehmannia glutinosa Libosch and …
Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror …
M Bioque, E Parellada, C García-Rizo… - European …, 2020 - cambridge.org
Background: Around 30% of patients with schizophrenia are considered treatment resistant
(TRS). Only around 40% of TRS patients respond to clozapine. Long acting injectable …
(TRS). Only around 40% of TRS patients respond to clozapine. Long acting injectable …
A review of paliperidone palmitate
P Chue, J Chue - Expert review of neurotherapeutics, 2012 - Taylor & Francis
Risperidone long-acting injection (RLAI) was the first second-generation antipsychotic
available as a long-acting injection. Paliperidone (9-hydroxyrisperidone) is the active …
available as a long-acting injection. Paliperidone (9-hydroxyrisperidone) is the active …
[HTML][HTML] Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review
Q Li, X Li, C Ye, M Jia, T Si - BMC psychiatry, 2024 - Springer
Background The utilization of once-monthly paliperidone palmitate (PP1M) in schizophrenia
treatment has increased due to its enhanced adherence and convenience. However, there …
treatment has increased due to its enhanced adherence and convenience. However, there …
[HTML][HTML] A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with …
D Coppola, Y Liu, S Gopal, B Remmerie, MN Samtani… - BMC psychiatry, 2012 - Springer
Background There are no previous reports of paliperidone palmitate's (PP) long term
tolerability or pharmacokinetics of the highest dose in patients with schizophrenia. This study …
tolerability or pharmacokinetics of the highest dose in patients with schizophrenia. This study …
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations
G Schoretsanitis, JM Meyer, A Conca… - Expert Opinion on Drug …, 2023 - Taylor & Francis
Introduction Long-acting injectable (LAI) formulations of second-generation antipsychotics
(SGA) are a mainstay in the treatment of schizophrenia-spectrum patients, and their use …
(SGA) are a mainstay in the treatment of schizophrenia-spectrum patients, and their use …